Aarti Drugs Limited’s Quarterly Result and Earnings Report for Q4(Mar 2024) : Sales decreased by 16.49 % in YoY and increased by 2.32 % in QoQ

The comprehensive analytics outlining the performance and outlook of Aarti Drugs Limited”s stock. This analysis encompasses various metrics including stock performance, investor sentiment, market trends, future outlook, risk factors, investment opportunities, long-term strategy, dividend policy, analyst insights, and the overall risk-reward profile. These insights aim to provide investors with a holistic understanding of the company”s stock, enabling informed decision-making and strategic investment planning.

Today, we’re looking at Aarti Drugs Limited’s financial performance for the Q4(Mar 2024).Starting with the top line, the company reported a significant year-over-year sales decline of -16.49 %. However, it did see a marginal increase of 2.32 % from the previous quarter. Expenses decreased slightly by -0.3 % quarter-on-quarter, aligning with the annual decline of -17.68 %. Operating profit, while down -8.26 % compared to last year, faced a quarter-on-quarter increase of 22.34 %, signaling a short-term expansion in margins.
The Operating Profit Margin (OPM) % echoes this narrative, showing resilience on an annual basis with an increase of 1.24 %, but an expansion of 2.26 % sequentially. Other income fell by -35.33 % compared to the last quarter, despite an annual growth of 24.14 %. Interest expenses surged remarkably by 20.13 % from the previous quarter, yet the year-over-year increase remains at a moderate 5.79 %. Depreciation costs climbed by 7.27 % quarter-on-quarter, whereas on an annual scale, they saw an increase of 8.64 %. Profit before tax declined annually by -12.42 % but saw an increase from the preceding quarter by 24.5 %.
Tax expenses as a percentage of profits increased slightly by 2.95 % compared to last year, with a more notable quarter-on-quarter decrease of -2.5 %. Net profit fell by -15.79 % year-on-year but experienced a 28.87 % expansion from the last quarter. And finally, Earnings Per Share (EPS) displayed an annual downturn of -15.16 % but a quarterly rise of 29.07 %. In summary, Aarti Drugs Limited’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.

In reviewing Aarti Drugs Limited’s 2024(Q4) financial snapshot, key trends emerge, shedding light on the company’s performance.Sales experienced a decrease of -16.49 % year-on-year, however, there was a minor increase of 2.32 % from the previous quarter. Expenses decreased by -17.68 % compared to the previous year, with a decrease of -0.3 % quarter-on-quarter. Operating Profit dropped by -8.26 % annually, and saw a 22.34 % increase from the last quarter.
Net Profit showed yearly decrease of -15.79 %, and experienced a 28.87 % increase from the previous quarter. Earnings Per Share (EPS) fell by -15.16 % annually, however rose by 29.07 % compared to the last quarter. In essence, while Aarti Drugs Limited faces strong annual decline indicators, short-term improvements suggest the potential for recovery and the importance of strategic adjustments to counter market challenges effectively. That’s all for now in the financial sector.